Screening/Prevention
September Is National Leukemia and Lymphoma Awareness Month
(09/02/2008)
As the month of September brings leukemia and lymphoma into focus, it’s a great time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated leukemia and lymphoma information throughout the year.
Cyclophosphamide May Increase Cancer Risk Among Patients with Rheumatoid Arthritis
(03/10/2008)
A large study conducted in Canada reveals that patients who are treated for rheumatoid arthritis (RA) with the drug cyclophosphamide may have an increased risk for developing hematological cancers such as lymphoma.
Being Overweight Associated with Increased Risk of Several Cancers
(02/19/2008)
Excess bodyweight increases the risk of developing several types of cancer, according to results recently published in The Lancet.
Vitamins During Pregnancy Decrease Childhood Cancer Risk
(02/23/2007)
According to an early online publication in the journal Clinical Pharmacology and Therapeutics, children of mothers who take vitamins during pregnancy have a decreased risk of pediatric brain tumors, neuroblastoma, and leukemia.
Aspartame Not Linked to Brain or Blood Cancer
(09/29/2006)
According to an article recently published in Cancer Epidemiology, Biomarkers and Prevention, high intake of aspartame (NutraSweet®) does not appear to increase the risks of cancers originating in the brain or blood.
More...
Chronic Lymphoblastic Leukemia
September Is National Leukemia and Lymphoma Awareness Month
(09/02/2008)
As the month of September brings leukemia and lymphoma into focus, it’s a great time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated leukemia and lymphoma information throughout the year.
Flavopiridol Has Significant Activity in Relapsed Chronic Lymphocytic Leukemia
(06/26/2008)
Flavopiridol provides pronounced anticancer activity among patients with chronic lymphocytic leukemia (CLL) that has stopped responding to prior therapies. These results were recently presented at the 2008 annual meeting of the American Society of Clinical Oncology in Chicago May 30-June 2.
Treanda® Included in NCCN Guidelines for CLL and NHL
(05/05/2008)
The chemotherapy agent Treanda® (bendamustine) has been added to the treatment guidelines of the National Comprehensive Cancer Network (NCCN) as an accepted treatment option for chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL).
FDA Approves Treanda® for Initial Treatment of Chronic Lymphocytic Leukemia
(04/25/2008)
The U.S. Food and Drug Administration has recently approved the drug Treanda® (bendamustine) for the treatment of chronic lymphocytic leukemia (CLL). The approval is based on data indicating that, for patients with CLL, Treanda improved overall response and complete response rates as well as progression-free survival rates compared with the commonly used agent chlorambucil.
HemeScan™ Evaluates Prognosis in Chronic Lymphocytic Leukemia
(02/11/2008)
A genetic test developed by CombiMatrix will soon be available to determine prognosis for chronic lymphocytic leukemia (CLL). The test, known as HemeScan™, has proven useful in the management of hematological malignancies such as leukemia and lymphoma.
More...
Acute Lymphoblastic Leukemia
September Is National Leukemia and Lymphoma Awareness Month
(09/02/2008)
As the month of September brings leukemia and lymphoma into focus, it’s a great time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated leukemia and lymphoma information throughout the year.
Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia
(08/12/2008)
The injection of stem cells collected from umbilical cords into the pelvic bone of patients with leukemia appears promising; however, longer follow-up is necessary to determine outcomes for these patients. These results were recently published in an early online publication of the Lancet Oncology.
Atovaquone Effectively Prevents Pneumocystis Carinii Pneumonia in Children
(07/20/2007)
According to the results of a study published in the journal Cancer, atovaquone (Mepron®, Malarone®) offers effective protection against Pneumocystis carinii pneumonia in children with leukemia.
Risk of Second Cancers Remains Long After Treatment for Childhood ALL
(03/28/2007)
According to an article recently published in the Journal of the American Medical Association, the risk of developing a second cancer increases over a 30-year period following treatment of childhood acute lymphoblastic leukemia (ALL).
Possible Link Between Magnetic Fields and Leukemia in Children with Down Syndrome
(01/22/2007)
According to the results of a study conducted in Mexico City, children with Down syndrome who have high household exposure to magnetic fields (energy produced by power lines and electrical devices) may have an increased risk of developing acute leukemia. These results were published in the journal Epidemiology.
More...
Acute Myeloid Leukemia
September Is National Leukemia and Lymphoma Awareness Month
(09/02/2008)
As the month of September brings leukemia and lymphoma into focus, it’s a great time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated leukemia and lymphoma information throughout the year.
Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia
(08/12/2008)
The injection of stem cells collected from umbilical cords into the pelvic bone of patients with leukemia appears promising; however, longer follow-up is necessary to determine outcomes for these patients. These results were recently published in an early online publication of the Lancet Oncology.
Prophylactic Use of Specific Antibiotics Reduce the Risk of Some Infections in AML
(07/28/2008)
Specific antibiotics used during remission (no evidence of disease) following induction therapy reduce the risk of some types of infection and associated complications among pediatric patients with acute myeloid leukemia. These results were published in an early on-line version in the journal Cancer.
Genetic Differences Associated with Outcomes in Acute Myeloid Leukemia
(05/01/2008)
It appears that different genetic mutations (alterations) affect outcomes among patients with acute myeloid leukemia. These results were recently published in the New England Journal of Medicine.
Nexavar® May Be More Effective in AML with Specific Mutations
(01/30/2008)
According to an article recently published in the Journal of the National Cancer Institute, the agent Nexavar® (sorafenib) appears to be effective in the treatment of acute myelogenous leukemia (AML) with specific mutations referred to as FLT3-ITD mutations.
More...
Acute Promyelocytic Leukemia
September Is National Leukemia and Lymphoma Awareness Month
(09/02/2008)
As the month of September brings leukemia and lymphoma into focus, it’s a great time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated leukemia and lymphoma information throughout the year.
Arsenic Trioxide Effective as Single Agent in Newly Diagnosed APL
(03/31/2006)
According to an article recently published in the journal Blood, the agent arsenic trioxide, when used as a single agent, provides impressive outcomes among patients with newly diagnosed acute promyelocytic leukemia.
Elderly with Acute Promyelocytic Leukemia Achieve Long-Term Survival with Treatment
(08/19/2004)
According to results published in a recent advanced online article in the journal Blood, long-term cancer-free survival can be achieved with treatment consisting of an anthracycline and ATRA for elderly patients with acute promyelocytic leukemia.
ATRA Plus Trisenox®: A Promising Treatment for Acute Promyelocytic Leukemia
(12/17/2003)
According to results presented at the 2003 annual meeting of the American Society of Hematology, the combination of all trans-retinoic acid (ATRA) and arsenic trioxide (Trisenox®) improves cancer-free survival compared with either agent alone in the treatment of acute promyelocytic leukemia.
Intensified Induction Therapy May Reduce Relapses in APL
(03/05/2002)
According to results recently presented at the 43
rd annual meeting of the American Society of Hematology, evidence suggests that patients with acute promyelocytic leukemia (APL) may have a low rate of cancer recurrence after intensified induction therapy including high dose cytarabine and all-trans retinoic acid (ATRA).
More...
Chronic Myeloid Leukemia
September Is National Leukemia and Lymphoma Awareness Month
(09/02/2008)
As the month of September brings leukemia and lymphoma into focus, it’s a great time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated leukemia and lymphoma information throughout the year.
LYN Kinase Affects Sensitivity to Gleevec® in Chronic Myeloid Leukemia
(07/01/2008)
A protein structure known as the LYN kinase appears to play an important role in the effectiveness of Gleevec® (imatinib mesylate) in chronic myeloid leukemia (CML) cancer cells. These results were recently published in the Journal of the National Cancer Institute.
Sprycel® Effective for Newly Diagnosed Chronic Myeloid Leukemia
(06/27/2008)
The targeted agent Sprycel® (dasatinib) is an effective treatment for patients newly diagnosed with chronic myeloid leukemia (CML). These results were recently presented at the 2008 annual meeting of the American Society of Clinical Oncology.
Tasigna® Effective for Patients with Newly Diagnosed Chronic Myeloid Leukemia
(06/25/2008)
The targeted agent Tasigna® (nilotinib) appears to be an effective treatment for patients with newly diagnosed chronic myeloid leukemia (CML). These results were recently presented at the 2008 annual meeting of the American Society of Clinical Oncology.
Advances in the Management of Chronic Myeloid Leukemia
(01/21/2008)
A Report from the 2007 American Society of Hematology (ASH) Meeting
More...
Hairy Cell Leukemia
September Is National Leukemia and Lymphoma Awareness Month
(09/02/2008)
As the month of September brings leukemia and lymphoma into focus, it’s a great time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated leukemia and lymphoma information throughout the year.
Patients with Hairy Cell Leukemia Have an Increased Risk of Second Cancers
(02/07/2007)
According to an article recently published in the Journal of the National Cancer Institute, patients with hairy cell leukemia are at an increased risk of developing a second cancer later in their lives.
Vaccine Highly Effective in Hairy Cell Leukemia
(09/19/2005)
According to a recent article published in the Journal of Clinical Oncology, the vaccine referred to as recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) is highly effective in the treatment of hairy cell leukemia (HCL).
Simple Diagnostic Test for Hairy Cell Leukemia
(08/30/2004)
According to a recent article published in The Lancet, a marker identified by gene profiling referred to as Annexin A1 (ANXA1) can help distinguish hairy cell leukemia from different kinds of leukemia.
Rituxan® Promising for Hairy Cell Leukemia
(12/01/2003)
According to a recent article published in the journal
Blood, Rituxan® (rituximab) produces high anti-cancer response rates in patients with hairy cell leukemia that has recurred following previous therapy.
More...